Skip to main content

COVID-19 Topic Center

Psychiatry Expert Insights

First Report Managed Care
According to the National Institutes of Health, schizophrenia is a chronic, severe, and disabling brain disorder affecting 2.4 million Americans, often with onset in early adulthood. The course of schizophrenia is varied, frequently involving periodic relapses of the disease with sometimes…
First Report Managed Care
While many pharmacy benefit and managed care strategies are designed to reduce the health care costs associated with schizophrenia, some of these tactics may actually unintentionally create barriers to treatment access. It’s an intriguing thought posed by Junqing Liu, PhD, MSW. “Despite the…
First Report Managed Care
San Diego—Long-acting injectable (LAI) antipsychotics are highly effective in the management of schizophrenia and associated with a number of potential advantages over oral antipsychotics. First-generation LAIs (LA1s) have been available for more than 50 years, while second-generation LAIs (…
Back to Top